MedTrace Logo

Schizophrenia Sensory Gating Deficit With Quetiapine

NCT00536783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2007-12-31

No results posted yet for this study

Summary

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.

Conditions

Interventions

DRUG

Quetiapine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • New Mexico VA Healthcare System

    lead FED

Principal Investigators

  • Jose M Canive, MD · New Mexico VA Heathcare System / BRINM

Eligibility

Min Age
18 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536783 on ClinicalTrials.gov